Kendall Square has become a hub of biotech innovation and a popular location for up and coming life sciences firms. Now, a ...

The global neurology clinical trials market is poised for substantial growth over the next decade, with projections forecasting an increase in market size from USD 5.7 billion in 2022 to a remarkable ...

Biogen’s pivot towards a more collaborative R&D model and its implications for the company’s pipeline and commercial strategy reflect a broader trend within the pharmaceutical industry to ...

Biogen’s pivot towards a more collaborative R&D model and its implications for the company’s pipeline and commercial strategy reflect a broader trend within the pharmaceutical industry to leverage ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment ...

Voyager Therapeutics Inc (VYGR) reports robust cash reserves and potential milestone payments, while advancing key gene ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June ...

Biogen will retain its commercial rights to the biosimilars already brought to market, as well as copycat version of Bayer's age-related macular degeneration blockbuster Eylea (aflibercept ...

regulatory and commercial milestones, as well as royalties on any future sales. BTK has become something of a hot target in MS research, and Biogen's deal follows Sanofi's $3.7 billion takeover of ...

The company recently secured approval for olezarsen in FCS, and looks odds on for a follow-up approval in SHTG. Click here to ...